|
rs1872328
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Taking a genome-wide association study approach, we identified inherited genetic variations in ACYP2 associated with cisplatin-related ototoxicity (rs1872328: P = 3.9 × 10(-8), hazard ratio = 4.5) in 238 children with newly diagnosed brain tumors, with independent replication in 68 similarly treated children.
|
25665007 |
2015 |
|
rs1872328
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The variant rs1872328 in the ACYP2 gene was recently identified as a risk factor for the development of cisplatin-induced ototoxicity in children with brain tumors.
|
26928270 |
2016 |
|
rs1800435
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We set out to determine if a less intensive method of exposure assessment (a job exposure matrix (JEM)) would produce similar results to a previous analysis that found evidence of effect modification of the association between expert-assessed lead exposure and risk of brain tumours by a single nucleotide polymorphism in the ALAD gene (rs1800435).
|
20798009 |
2011 |
|
rs113994087
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
|
22072639 |
2011 |
|
rs113994088
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
|
22072639 |
2011 |
|
rs113994089
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.
|
22072639 |
2011 |
|
rs1801516
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The involvement of ATM gene and specifically, the important role of D1853N polymorphism, as a three-hit hypothesis has been previously reported in an Iranian proband affected with brain tumor and this polymorphism could be screened in her relatives as well.
|
20396981 |
2011 |
|
rs1801516
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The current study was conducted to query possible correlations among methylation statue of ATM gene, ATM/ retinoblastoma (RB) protein expression, D1853N ATM polymorphism, telomere length (TL), and clinicopathological characteristics of various types of brain tumors.
|
25159481 |
2015 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Among brain tumors, the BRAF (V600E) mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs).
|
26264609 |
2015 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
An activating mutation of BRAF (BRAF-V600E) has been reported in a subset of malignant brain tumors.
|
24721513 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Future clinical trials should address whether BRAF V600E mutant brain tumour patients will benefit from BRAF V600E-directed targeted therapies.
|
24353007 |
2014 |
|
rs113488022
|
|
T |
0.800 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
PKM2-regulated MLC2 phosphorylation, which is greatly enhanced by EGF stimulation or EGFRvIII, K-Ras G12V and B-Raf V600E mutant expression, plays a pivotal role in cytokinesis, cell proliferation and brain tumour development.
|
25412762 |
2014 |
|
rs113488022
|
|
T |
0.800 |
GeneticVariation |
CLINVAR |
Targeted therapy for BRAFV600E malignant astrocytoma.
|
22038996 |
2011 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation and KIAA1549-BRAF fusion are alterations found in several brain tumors and show a distinct prognostic impact in some entities.
|
31181803 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Efficacy of BRAF V600E targeted therapies in brain tumors harboring the mutation has been shown in several case reports and is currently being studied in larger clinical trials.
|
29380516 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This report presents 2 cases of malignant brain tumors with <i>BRAF</i> V600E mutations that were resistant to radiation and temozolomide, and reports on their response to targeted treatment with the BRAF and MEK inhibitors dabrafenib and trametinib.
|
29632053 |
2018 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Epithelioid glioblastoma is a recognized glioblastoma variant, recently added to the World Health Organization brain tumor classification, with similar prognosis as the classic variant and B-Raf V600E mutations in 50% of the cases.
|
31258848 |
2019 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The BRAF V600E mutation occurs frequently in certain brain tumors such as pleomorphic xanthoastrocytoma, ganglioglioma, and pilocytic astrocytoma, and less frequently in epithelioid and giant cell glioblastoma.
|
25885250 |
2015 |
|
rs113488022
|
|
T |
0.800 |
GeneticVariation |
CLINVAR |
Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy.
|
22586120 |
2012 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
BRAF V600E-mutations have been described in a modest 6% to 7% of primary central nervous system (CNS) tumors, but with increased prevalence in the pediatric population and in certain brain tumor subtypes.
|
24725538 |
2014 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The patient's resected brain tumor is BRAF V600E mutated, NRAS wild type (WT), and TERT C250T mutated.
|
26597176 |
2015 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Future clinical trials should address whether BRAF (V600E) mutant brain tumor patients will benefit from BRAF (V600E)-directed targeted therapies.
|
21274720 |
2011 |
|
rs113488022
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Therefore the BRAF V600E mutation is a highly interesting oncological target in brain tumors.
|
27350555 |
2016 |